Signal
Kazia Therapeutics Expands Paxalisib Clinical Trial to HR+/HER2- Breast Cancer Patients
- Category
- · Research · Global
- Date
- September 1, 2026
- Source
- OVUM
Summary
Following positive preclinical data, Kazia is expanding its ongoing triple-negative breast cancer trial to include HR+/HER2- patients. The study will evaluate paxalisib combined with fulvestrant and palbociclib, targeting a critical gap in treatment for the most common breast cancer subtype.
The finding adds to the evidence in Oncology and Therapeutics. Read it alongside earlier studies asking the same question. Companies whose products depend on clinical proof feel this kind of result first.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.